OBJECTIVE: To compare neurodevelopmental outcomes using Bayley Scales of Infant Development (BSID), between encephalopathic neonates undergoing therapeutic hypothermia (TH), sedated with either continuous dexmedetomidine or intermittent morphine. STUDY DESIGN: Retrospective, observational cohort study including encephalopathic neonates born between 2014 - 2022 that underwent TH at two Regional Perinatal Centres, and completed neurodevelopmental follow-up assessments. RESULTS: There were no significant differences in demographics or short-term neurologic outcomes between morphine (n = 30) and dexmedetomidine (n = 32) groups. At 12 months, median motor composite scores (104 vs 98.5, p = 0.02) and median fine motor scaled scores (SS) (11 vs 10, p = 0.01) were significantly higher in the dexmedetomidine group. Median expressive language SS were slightly higher in the morphine group (11 v 10, p = 0.05). BSID scores at 18-24 months were similar. CONCLUSION: This study supports the use of dexmedetomidine as first-line sedation agent during TH, given comparable 18-24 month neurodevelopmental outcomes.